{
    "organizations": [],
    "uuid": "168497cb8b647a6bad0a8363e3d7c8648d55cad8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-shield-therapeutics-says-top-line/brief-shield-therapeutics-says-top-line-results-from-aegis-ckd-pivotal-phase-iii-study-of-feraccru-idUSFWN1PV0BB",
    "ord_in_thread": 0,
    "title": "BRIEF-Shield Therapeutics Says Top-Line Results From Aegis-Ckd Pivotal Phase III Study Of Feraccru​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 5 (Reuters) - Shield Therapeutics Plc:\n* ‍ANNOUNCES TOP-LINE RESULTS FROM ITS AEGIS-CKD PIVOTAL PHASE III STUDY OF FERACCRU​\n* ‍PRIMARY EFFICACY ENDPOINT NOT ACHIEVED​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-05T15:24:00.000+02:00",
    "crawled": "2018-02-06T23:52:48.018+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "shield",
        "therapeutic",
        "plc",
        "result",
        "pivotal",
        "phase",
        "iii",
        "study",
        "efficacy",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}